抄録
The standard therapy for early-stage non-small cell lung cancer (NSCLC) is pulmonary lobectomy. However,
the Evidence-based Clinical Practice Guidelines for Lung Cancer of 2017 (the Japan Lung Cancer Society) recommend that stereotactic body radiotherapy (SBRT) should be performed as a curative treatment in patients who
cannot undergo surgery for medical reasons. SBRT is highly effective against early-stage NSCLC and the adverse
events due to RT are tolerable. We have noted the indication of SBRT for early-stage NSCLC.
